Publications

Detailed Information

Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM

DC Field Value Language
dc.contributor.authorPark, Hyunkyung-
dc.contributor.authorByun, Ja Min-
dc.contributor.authorYoon, Sung-Soo-
dc.contributor.authorKoh, Youngil-
dc.contributor.authorYoon, Sock-Won-
dc.contributor.authorShin, Dong-Yeop-
dc.contributor.authorHong, Junshik-
dc.contributor.authorKim, Inho-
dc.date.accessioned2022-06-24T08:26:50Z-
dc.date.available2022-06-24T08:26:50Z-
dc.date.created2022-05-13-
dc.date.issued2022-01-
dc.identifier.citationPLoS ONE, Vol.17 No.1 January, p. e0260113-
dc.identifier.issn1932-6203-
dc.identifier.urihttps://hdl.handle.net/10371/184082-
dc.description.abstract© 2022 Park et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.In the backdrop of rapidly changing relapsed/refractory (RR) multiple myeloma (MM) treatment schema that mainly evolves around immunotherapies, it is easy to disregard more traditional drugs. Finding the best partner for pomalidomide, a potent third-generation immunomodulatory drug, is an important agenda we face as a community and cyclophosphamide addition has been used for outcomes augmentation. We carried out this real-world study to identify patients who will show durable response to pomalidomide and those who will benefit from cyclophosphamide addition. A total of 103 patients (57 in pomalidomidedexamethasone [Pd] group versus 46 in pomalidomide-cyclophosphamide-dexamethasone [PCd]) were studied. They were previously treated with bortezomib (98.1%) or lenalidomide (100%) and previous lines of therapy were median 3 lines. Significantly better overall response rate (ORR) was seen in the PCd (75.6%) than Pd (41.7%) group (p = 0.001), but no differences in survival outcomes. Subgroup analysis revealed that high-risk myeloma features, poor response to lenalidomide or bortezomib had superior ORRs when cyclophosphamide was added. Also, long-term responders for pomalidomide were associated with excellent response to previous IMiD treatments. Pomalidomide-based therapy was discontinued in five patients due to intolerance or adverse events, but there was no mortality during treatment. In conclusion, we showed that pomalidomide-based treatment is still relevant and can ensure durable response in RRMM setting, especially for patients who responded well to previous lenalidomide. Addition of cyclophosphamide to Pd is associated with better ORR, and can be positively considered in fit patients with high-risk MM, extramedullary disease, and less-than-satisfactory response to previous lenalidomide treatment.-
dc.language영어-
dc.publisherPublic Library of Science-
dc.titleCyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM-
dc.typeArticle-
dc.identifier.doi10.1371/journal.pone.0260113-
dc.citation.journaltitlePLoS ONE-
dc.identifier.wosid000779379600011-
dc.identifier.scopusid2-s2.0-85123707240-
dc.citation.number1 January-
dc.citation.startpagee0260113-
dc.citation.volume17-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorYoon, Sung-Soo-
dc.contributor.affiliatedAuthorHong, Junshik-
dc.type.docTypeArticle-
dc.description.journalClass1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share